RECURSION PHARMACEUTICALS, INC. Repayments of Long-Term Debt
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Repayments of Long-Term Debt of $52.00 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2024-08-08
- RECURSION PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2024-06-30 was $26.00K, a 8.33% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2024-03-31 was $26.00K, a 8.33% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2023-12-31 was $694.00K, a 2917.39% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2023-09-30 was $24.00K, a 4.35% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2023 was $766.00K, a 751.11% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2022 was $90.00K, a 99.30% decline from fiscal 2021.
- RECURSION PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2021 was $12.80M, a 16520.78% increase from fiscal 2020.
- RECURSION PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2020 was $77.00K, a 99.31% decline from fiscal 2019.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2024-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $52.00K 10-Q · filed 2024-08-08 | $746.00K derived: sum of 3 quarters · filed 2024-08-08 | $770.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | $26.00K 10-Q · filed 2024-05-09 | $720.00K derived: sum of 2 quarters · filed 2024-05-09 | $744.00K derived: sum of 3 quarters · filed 2024-05-09 | $768.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-12-31 | $694.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $718.00K derived: sum of 2 quarters · filed 2024-02-29 | $742.00K derived: sum of 3 quarters · filed 2024-08-08 | $766.00K 10-K · filed 2024-02-29 |
| 2023-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $48.00K derived: sum of 2 quarters · filed 2024-08-08 | $72.00K 10-Q · filed 2023-11-09 | $95.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $48.00K 10-Q · filed 2024-08-08 | $71.00K derived: sum of 3 quarters · filed 2024-08-08 | $94.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $24.00K 10-Q · filed 2024-05-09 | $47.00K derived: sum of 2 quarters · filed 2024-05-09 | $70.00K derived: sum of 3 quarters · filed 2024-05-09 | $92.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $46.00K derived: sum of 2 quarters · filed 2024-02-29 | $68.00K derived: sum of 3 quarters · filed 2024-02-29 | $90.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $45.00K derived: sum of 2 quarters · filed 2023-11-09 | $67.00K 10-Q · filed 2023-11-09 | $88.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $44.00K 10-Q · filed 2023-08-08 | $65.00K derived: sum of 3 quarters · filed 2024-02-29 | $12.80M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $22.00K 10-Q · filed 2023-05-08 | $43.00K derived: sum of 2 quarters · filed 2024-02-29 | $12.78M derived: sum of 3 quarters · filed 2024-02-29 | $12.80M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $12.76M derived: sum of 2 quarters · filed 2024-02-29 | $12.78M derived: sum of 3 quarters · filed 2024-02-29 | $12.80M 10-K · filed 2024-02-29 |
| 2021-09-30 | $12.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $12.76M derived: sum of 2 quarters · filed 2022-11-08 | $12.78M 10-Q · filed 2022-11-08 | $12.80M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $40.00K 10-Q · filed 2022-08-09 | $60.00K derived: sum of 3 quarters · filed 2023-02-27 | $80.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $20.00K 10-Q · filed 2022-05-10 | $40.00K derived: sum of 2 quarters · filed 2023-02-27 | $60.00K derived: sum of 3 quarters · filed 2023-02-27 | $78.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $40.00K derived: sum of 2 quarters · filed 2023-02-27 | $58.00K derived: sum of 3 quarters · filed 2023-02-27 | $77.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $38.00K derived: sum of 2 quarters · filed 2021-11-10 | $57.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $37.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $19.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $11.18M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |